Intellipharmaceutics International Inc.
IPCIF · OTC
8/31/2023 | 5/31/2023 | 2/28/2023 | 11/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $0 | $0 | $0 | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $1 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $0 | $0 | $0 |
| Total Curr. Assets | $1 | $1 | $1 | $0 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | -$0 | -$0 | -$0 | -$0 |
| Total NC Assets | $1 | $1 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $2 | $2 | $2 | $1 |
| Liabilities | – | – | – | – |
| Payables | $4 | $4 | $4 | $4 |
| Short-Term Debt | $2 | $2 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $4 | $3 | $3 | $2 |
| Total Curr. Liab. | $14 | $13 | $13 | $12 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $14 | $13 | $13 | $12 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $49 | $49 | $49 | $49 |
| Retained Earnings | -$107 | -$106 | -$105 | -$105 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $45 | $45 | $45 | $45 |
| Total Equity | -$13 | -$11 | -$11 | -$11 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $2 | $2 | $2 | $1 |
| Net Debt | $2 | $2 | $2 | $2 |